

Galmed Pharmaceuticals Ltd.  
Form 6-K  
July 31, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of July 2017

001-36345

(Commission File Number)

**GALMED PHARMACEUTICALS LTD.**

(Exact name of Registrant as specified in its charter)

**16 Tiomkin St.**

**Tel Aviv 6578317, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

Form 20-F x Form 40-F "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): \_\_\_\_\_

This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. (the “Company”), which includes the Company’s unaudited consolidated financial statements for the three and six months ended June 30, 2017, together with related information and certain other information. The Company is not subject to the requirements to file quarterly or certain other reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company does not undertake to file or cause to be filed any such reports in the future, except to the extent required by law.

On July 31, 2017, the Company issued a press release announcing the filing of its financial results for the three and six months ended June 30, 2017 with the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Form 6-K and the text under the heading “Financial Summary - Second Quarter 2017 vs. Second Quarter 2016” in Exhibit 99.1 is incorporated by reference into the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 11, 2015 (Registration No. 333-206292) and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 31, 2015 (Registration No. 333-203133).

## FINANCIAL INFORMATION

*Financial Statements***GALMED PHARMACEUTICALS LTD.****Consolidated Balance Sheets****U.S. Dollars in thousands, except share data and per share data**

	As of June 30, 2017 Unaudited	As of December 31, 2016 Audited
Assets		
Current assets		
Cash and cash equivalents	\$ 1,747	\$ 3,097
Marketable securities	7,408	12,351
Other accounts receivable	266	284
Total current assets	9,421	15,732
Property and equipment, net	606	718
Total assets	\$ 10,027	\$ 16,450
Liabilities and stockholders' equity		
Current liabilities		
Trade payables	\$ 2,365	\$ 3,122
Other accounts payable	185	363
Short-term portion of deferred revenue	1,085	1,094
Total current liabilities	3,635	4,579
Long-term liabilities		
Related parties	150	267
Long-term portion of deferred revenue	-	529
Total long-term liabilities	150	796
Stockholders' equity:		
Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding: 12,219,186 shares as of June 30, 2017; 12,149,226 shares as of December 31, 2016	34	34
Additional paid-in capital	76,402	75,446
Accumulated other comprehensive loss	(20 )	(85 )

Edgar Filing: Galmed Pharmaceuticals Ltd. - Form 6-K

Accumulated deficit	(70,174 )	(64,320 )
Total stockholders' equity	6,242	11,075
Total liabilities and stockholders' equity	\$ 10,027	\$ 16,450

The accompanying notes are an integral part of the interim consolidated financial statements.

**GALMED PHARMACEUTICALS LTD.**  
**Consolidated Statements of Operations (Unaudited)**  
**U.S. Dollars in thousands, except share data and per share data**

	Three months ended		Six months ended	
	June 30,	2016	June 30,	2016
	2017		2017	2016
Revenue	\$270	\$-	\$538	\$-
Research and development expenses	2,347	3,360	5,090	6,744
General and administrative expenses	624	861	1,413	1,580
Total operating expenses	2,701	4,221	5,965	8,324
Financial expenses (income), net	(9 )	89	(111 )	(30 )
Loss before income taxes	2,692	4,310	5,854	8,294
Taxes on Income	-	1	-	1
Net loss	\$2,692	\$4,311	\$5,854	\$8,295
Basic and diluted net loss per share	\$0.22	\$0.39	\$0.48	\$0.75
Weighted-average number of shares outstanding used in computing basic and diluted net loss per share	12,175,147	11,100,853	12,171,668	11,100,655

The accompanying notes are an integral part of the interim consolidated financial statements.

**GALMED PHARMACEUTICALS LTD.**  
**Consolidated Statements of Comprehensive Loss (Unaudited)**  
**U.S. Dollars in thousands**

	Three months ended		Six months ended	
	June 30,		June 30,	
	2017	2016	2017	2016
Net loss	\$ 2,692	\$ 4,311	\$ 5,854	\$ 8,295
Other comprehensive loss (income):				
Net unrealized loss (gain) on available for sale securities	(41 )	(56 )	(65 )	(102 )
Comprehensive loss	\$ 2,651	\$ 4,255	\$ 5,789	\$ 8,193

The accompanying notes are an integral part of the interim consolidated financial statements.

**GALMED PHARMACEUTICALS LTD.****Consolidated Statements of Changes in Stockholders' Equity (Unaudited)****U.S. Dollars in thousands, except share data and per share data**

	Ordinary shares		Additional paid-in	Accumulated other Comprehensive	Accumulated	
	Shares	Amount	capital	loss	Deficit	Total
Balance - December 31, 2016	12,149,226	\$ 34	\$ 75,446	\$ (85	) \$ (64,320	) \$11,075
Stock based compensation	-	-	709	-	-	709
Issuance of Ordinary Shares (*)	69,960	-	247	-	-	247
Unrealized gain from marketable securities	-	-	-	65	-	65
Net loss	-	-	-	-	(5,854	) (5,854)
Balance - June 30, 2017	12,219,186	\$ 34	\$ 76,402	\$ (20	) \$ (70,174	) \$6,242

(\*) See note 3.3 and 3.4

The accompanying notes are an integral part of the interim consolidated financial statements.



**GALMED PHARMACEUTICALS LTD.**  
**Consolidated Statements of Cash Flows (Unaudited)**  
**U.S. Dollars in thousands**

	<b>Six months ended</b>	
	<b>June 30,</b>	
	2017	2016
Cash flow from operating activities		
Net loss	\$(5,854)	\$(8,295)
Adjustments required to reconcile net loss to net cash used in operating activities		
Depreciation and amortization	120	66
Stock-based compensation expense	709	1,063
Amortization of discount/premium on marketable securities	(207 )	35
Loss from Realization of marketable securities	115	138
Changes in operating assets and liabilities:		
Decrease in other accounts receivable	18	43
Increase (decrease) in trade payables	(757 )	706
Increase (decrease) in other accounts payable	(178 )	106
Increase (decrease) in related party	(117 )	45
Decrease in deferred revenue	(538 )	-
Net cash used in operating activities	(6,689)	(6,093)
Cash flow from investing activities		
Purchase of property and equipment	(8 )	(23 )
Investment in securities, available for sale	-	(1,212)
Consideration of securities, available for sale	5,100	6,250
Net cash provided in (used in) investing activities	5,092	5,015
Cash flow from financing activities		
Issuance of ordinary shares	247	11
Deferred issuance costs	-	(143 )
Net cash used in financing activities	247	(132 )
Increase (decrease) in cash and cash equivalents	(1,350)	(1,210)
Cash and cash equivalents at the beginning of the year	3,097	4,156
Cash and cash equivalents at the end of the period	\$1,747	\$2,946
Supplemental disclosure of cash flow information:		
Cash received from interest	\$136	223

The accompanying notes are an integral part of the interim consolidated financial statements.

**GALMED PHARMACEUTICALS LTD.**  
**Notes to Consolidated Financial Statements**

**Note 1 - Basis of presentation**

Galmed Pharmaceuticals Ltd. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases.

The Company in its current legal structure was incorporated in Israel on July 31, 2013 as a privately held company, and formally commenced operations on February 2, 2014. However, the Company’s business has been operating since 2000 under a different group of companies established in 2000 (the “Group”). On February 2, 2014, upon a pre-ruling from the Israeli Tax Authorities, the Company underwent a reorganization (the “Reorganization”), pursuant to which all of the business of its predecessor, Galmed Holdings Inc., including net assets and shares in its wholly-owned subsidiary, Galmed 2000, Inc. were transferred to the Company. Contemporaneously, the Company effected a 729-for-1 stock split.

These unaudited interim consolidated financial statements have been prepared as of June 30, 2017 and for the three and six month period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2016 that are included in the Company's Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 23, 2017 (the "Annual Report"). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2017.

**Note 2 - Summary of significant accounting policies**

The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F.

**Note 3 - Stockholders' Equity**

1. In January 2017, the Company granted options to purchase 130,000 ordinary shares of the Company, NIS 0.01 par value per share, to certain officers and employees. The options are exercisable at \$3.84 per share, have a 10 year term and vest over a period of four years. The aggregate grant date fair value of such options is approximately \$376 thousand.

2. In April 2017, the Company granted options to purchase 30,000 ordinary shares of the Company, NIS 0.01 par value per share, to two of its consultants. The options have an exercise price ranging between \$4.75 and \$4.87 per share, have a 10 year term and vest over a period of between one to four years. The aggregate grant date fair value of such options is approximately \$99 thousand.

3. During June 2017, certain officers and former employees exercised 46,218 options into ordinary shares of the Company, NIS 0.01 par value per share, for total consideration of \$247 thousand.

4. During the first half of 2017, a total of 23,742 restricted stock units were exercised into 23,742 ordinary shares of the Company, NIS 0.01 par value per share.

## Management's Discussion and Analysis of Financial Condition and Results of Operations

*All references to “we,” “us,” “our,” “the Company” and “our Company”, in this Form 6-K are to Galmed Pharmaceuticals Ltd. and its subsidiaries, unless the context otherwise requires. All references to “shares” or “ordinary shares” are to our ordinary shares, NIS 0.01 nominal par value per share. All references to “Israel” are to the State of Israel. “U.S. GAAP” means the generally accepted accounting principles of the United States. Unless otherwise stated, all of our financial information presented in this Form 6-K has been prepared in accordance with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts and percentages listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this Form 6-K to financial and operational data for a particular year refer to the fiscal year of our company ended December 31 of that year.*

*Our reporting currency and financial currency is the U.S. dollar. In this Form 6-K, “NIS” means New Israeli Shekel, and “\$,” “US\$” and “U.S. dollars” mean United States dollars.*

### Cautionary Note Regarding Forward-Looking Statements

This Form 6-K contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,” “will,” “project,” “continue” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included in, among other things, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below:

the timing and cost of our ongoing Phase IIB ARREST Study, and planned Phase III trials, for our product candidate, Aramchol™ (hereinafter referred to as “Aramchol”) for the treatment of patients who are overweight or obese and have pre diabetes or type II diabetes mellitus (hereinafter OD patients) with Non-Alcoholic Steato-Hepatitis, or NASH, or whether Phase III trials will be conducted at all;

- completion and receiving favorable results of these Phase IIB ARREST Study and Phase III trials for Aramchol;

- regulatory action with respect to Aramchol by the U.S. Food and Drug Administration, or FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling;

- the commercial launch and future sales of Aramchol or any other future products or product candidates;

- our ability to comply with all applicable post-market regulatory requirements for Aramchol in the countries in which we seek to market the product;

- our ability to achieve favorable pricing for Aramchol;

- our expectations regarding the commercial market for NASH in OD patients;

- third-party payor reimbursement for Aramchol;

- our estimates regarding anticipated capital requirements and our needs for additional financing;

- market adoption of Aramchol by physicians and patients;

- the timing, cost or other aspects of the commercial launch of Aramchol;

- the development and approval of the use of Aramchol for additional indications or in combination therapy; and

- our expectations regarding licensing, acquisitions and strategic operations.

We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the SEC on March 23, 2017 in greater detail under the heading "Risk Factors" and elsewhere in the Annual Report and this Form 6-K. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

## **Overview**

We are a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. We are currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in 248 subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Top line data from the ARREST Study are expected to be available during the second quarter of 2018.

We also sponsor the ARRIVE Study, a proof-of-concept Phase IIa clinical trial designed to evaluate the safety and efficacy of Aramchol in up to 50 patients with HIV-associated NAFLD (Non-Alcoholic Fatty Liver Disease) and lipodystrophy. The ARRIVE Study is an investigator-initiated trial, conducted at the University of California San Diego by Professor Rohit Loomba. More information about the ARREST Study and the ARRIVE Study may be found on ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591, respectively.

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. We are investing efforts into better understanding the mechanisms by which Aramchol<sup>TM</sup> down regulates steatosis and fibrosis. Additional animal models are being investigated with a variety of treatment regimens. The data, thus far, demonstrates dual mode of action of Aramchol on fibrosis via improvement of Fatty Acid oxidation as well a direct impact on stellate cells which are the collagen producing cells in the liver which results

in reversing fibrosis. Aramchol has been granted by the FDA Fast Track designation status for the treatment of NASH.

## Financial Overview

We have funded our operations primarily through the sale of equity and debt securities in private equity and debt financings in Israel to our affiliates (which has subsequently been converted in whole into common equity; no debt remains on our balance sheet), shareholders and third-party investors, and as of March 18, 2014, through the sale of our ordinary shares in our initial public offering. At June 30, 2017, we had current assets of \$9.4 million, which consists of cash and cash equivalents of \$1.7 million and short-term investment securities of \$7.4 million. This compares with current assets of \$15.7 million at December 31, 2016, which consists of cash and cash equivalents of \$3.1 million and short-term investment securities of \$12.4 million. Although we provide no assurance, we believe that such existing funds will be sufficient to continue our business and operations as currently conducted through the first half of 2018. However, we will continue to incur operating losses, which may be substantial over the next several years, and we may need to obtain additional funds to complete the ARREST Study, and further develop our research and development programs.

## Recent Developments

During the second quarter of 2017, we announced the following developments:

In April, we presented at the International Liver Congress data that shows that Aramchol™ has a potential direct effect on liver fibrosis.

On June 8, 2017, we announced the election of Dr. Carol L. Brosgart as a new member of our board of directors.

Since the end of the second quarter of 2017 (subsequent to the balance sheet date), we had the following developments:

The DMC for the ARREST study met in July to review the accumulated safety data. Following review of the data the DMC issued a positive recommendation for the continuation of the clinical trial with no changes to the protocol.

Dr. Tali Gorfine, our CMO, is currently on medical leave. Prof. Ran Oren, a member of our board of directors and our medical consultant (previously acted as the Company's CMO), together with Dr. Serena Rosner, M.D., who is working with Dr. Gorfine, have temporarily assumed Dr. Gorfine's duties in her absence.





## **Revenues**

On July 28, 2016, we entered into a license agreement, referred to herein as the Samil Agreement, with Samil Pharma. Co., Ltd. for the commercialization of Aramchol (with the option to manufacture) in the Republic of Korea. Under the terms of the Samil Agreement, we have received upfront payments of \$2.1 million, and may be eligible to receive up to \$6.0 million in additional payments for development and regulatory milestones for Aramchol in the licensed territories. For accounting purposes, the upfront payment has been recorded as deferred revenue. The deferred revenue is then amortized on a straight-line basis over the contractual period and milestone payments are recognized once earned.

## **Costs and Operating Expenses**

Our current costs and operating expenses consist of two components: (i) research and development expenses; and (ii) general and administrative expenses.

### ***Research and Development Expenses***

Our research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and fees paid to external service providers, patent-related legal fees, costs of preclinical studies and clinical trials and drug and laboratory supplies. We charge all research and development expenses to operations as they are incurred. We expect our research and development expenses to remain our primary expenses in the near future as we continue to conduct clinical activities, as well as develop our products. Increases or decreases in research and development expenditures are attributable to the number or duration of the preclinical and clinical studies that we conduct.

We expect that a large percentage of our research and development expense in the future will be incurred in support of our current and future clinical and, to a lesser extent, preclinical development projects. Due to the inherently unpredictable nature of clinical and preclinical development processes, we are unable to estimate with any certainty the costs we will incur in the continued development of Aramchol for NASH and other indications in our pipeline for potential commercialization. Clinical development timelines, the probability of success for any given study, and development costs can differ materially from expectations. We expect to continue to conduct additional clinical trials for Aramchol, and to test Aramchol in preclinical studies for toxicology, safety and efficacy.

While we are currently focused on advancing our product development, our future research and development expenses will depend on the clinical success of Aramchol, as well as ongoing assessments of Aramchol's commercial potential. As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for Aramchol in certain indications in order to focus our resources on more promising indications for Aramchol. Completion of clinical trials may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of Aramchol.

We expect our research and development expenses to increase in the future from current levels as we continue the advancement of our clinical product development and potentially in-license new product candidates. The lengthy process of completing clinical trials and seeking regulatory approval for Aramchol requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

### ***General and Administrative Expenses***

General and administrative expenses consist primarily of compensation for employees in executive and operational roles, including accounting, finance, legal and investor relations. Our other significant general and administrative expenses include non-cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv, Israel), professional fees for outside accounting and legal services, travel costs, investors relations, insurance premiums and depreciation.

We expect our general and administrative expenses, such as accounting and legal fees, to increase as we grow and operate as a public company, and we expect an increase in our salary and benefits expense as a result of the additional management and operational personnel that we hired since our initial public offering to address the anticipated growth of our company, as well as performance-based salary increases and bonuses, if at all.

### ***Financial Income, Net***

Our financial income consists of interest income from marketable securities and short-term bank deposits. Our financial expense consists of bank fees.

## Results of Operations

The table below provides our results of operations for the three and six months ended June 30, 2017 as compared to the three and six months ended June 30, 2016.

	Three months ended June 30,		Six months ended June 30,	
	2017	2016	2017	2016
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	(In thousands, except per share data)			
Revenue	270	-	538	-
Research and development expenses	2,347	3,360	5,090	6,744
General and administrative expenses	624	861	1,413	1,580
Total operating expenses	2,701	4,221	5,965	8,324
Financial expenses (income), net	(9 )	89	(111 )	(30 )
Taxes on income	-	1	-	1
Net loss	2,692	4,311	5,854	8,295
Other comprehensive income:	(41 )	(56 )	(65 )	(102 )
Comprehensive loss	2,651	4,255	5,789	8,193
Basic and diluted net loss per share	\$0.22	\$ 0.39	\$ 0.48	\$ 0.75

### Revenue

Licensing revenue was approximately \$270 thousand and approximately \$538 thousand for the three and six months ended June 30, 2017, compared to no revenue for the three and six months ended June 30, 2016. The above mentioned revenue resulted from the amortization of the up-front payments under the license agreement with Samil Pharm.

### Research and Development Expenses

Our research and development expenses amounted to approximately \$2.3 million and approximately \$5.1 million during the three and six months ended June 30, 2017, respectively, representing a decrease of approximately \$1.1 million, or 32%, and approximately \$1.6 million, or 24%, respectively, compared to approximately \$3.4 million and approximately \$6.7 million for the comparable period in 2016.

The decrease during the three months ended June 30, 2017 primarily resulted from a decrease of approximately \$718 thousand in subcontractor expenses in connection with the ARREST Study, as well as a decrease of non-cash stock-based compensation expenses of approximately \$376 thousand, as compared to such expenses for the comparable period in 2016.

The decrease during the six months ended June 30, 2017 primarily resulted from a decrease of approximately \$594 thousand in subcontractor expenses in connection with the ARREST Study, as well as decreases of approximately \$557 thousand in drug development related expenses and approximately \$333 thousand in non-cash stock-based compensation expenses, as compared to such expenses for the comparable period in 2016.

### ***General and Administrative Expenses***

Our general and administrative expenses amounted to approximately \$624 thousand and approximately \$1.4 million during the three and six months ended June 30, 2017, respectively, representing a decrease of approximately \$237 thousand, or 28%, and \$167 thousand, or 11%, respectively, compared to approximately \$861 thousand and approximately \$1.6 million for the comparable period in 2016.

The decrease during the three months ended June 30, 2017 primarily resulted from a decrease of approximately \$170 thousand in salaries and benefits, consisting of non-cash stock-based compensation and salaries paid to employees, as well as a decrease of approximately \$80 thousand in professional fees, as compared to such expenses for the comparable period in 2016.

The decrease during the six months ended June 30, 2017 primarily resulted from a decrease of approximately \$131 thousand in professional fees, as compared to such fees for the comparable period in 2016.

### ***Operating Loss***

As a result of the foregoing, for the three and six months ended June 30, 2017, our operating loss was approximately \$2.7 million and approximately \$6.0 million, respectively, representing a decrease of \$1.5 million, or 36%, and \$2.3 million, or 28%, respectively, as compared to our operating loss for the comparable prior year period. These decreases for the three and six months ended June 30, 2017 primarily resulted from a decrease in our research and development expenses as well as from our licensing revenue.

***Financial (Income) Expense, Net***

Our financial (income) expense amounted to approximately (\$9) thousand and approximately (\$111) thousand during the three and six months ended June 30, 2017, respectively, compared to \$89 thousand and (\$30) thousand for the comparable period in 2016.

The decrease during the three and six months ended June 30, 2017 primarily resulted from an increase in currency exchange rates expenses, as compared to such expenses for the comparable period in 2016.

***Net Loss***

As a result of the foregoing, for the three and six months ended June 30, 2017, our net loss was \$2.7 million and \$5.9 million, respectively, representing a decrease of \$1.6 million, or 37%, and \$2.4 million, or 29%, respectively, as compared to our net loss for the comparable prior year period.

**Liquidity and Capital Resources**

To date, we have funded our operations primarily through the sale of equity and debt securities in private equity offerings and debt financings in Israel to our affiliates (that has subsequently been converted in whole to common equity; no debt or debt-related securities remains on our balance sheet), shareholders and third-party investors, and as of March 18, 2014, through the sale of our ordinary shares in our initial public offering (approximately \$39.9 million of net proceeds) and through our ATM Offering (approximately \$4.5 million of net proceeds), and as well, through the upfront payment received from Samil (approximately \$2.1 million). Furthermore, under our Sales Agreement, we may still raise up to approximately \$11.5 million through the sale of additional ordinary shares in our ATM Offering, which was last used during September, 2016.

We have incurred substantial losses since our inception. As of June 30, 2017, we had an accumulated deficit of approximately \$70.2 million and positive working capital (current assets less current liabilities) of approximately \$5.8 million. We expect that operating losses will continue for the foreseeable future.

As of June 30, 2017, we had cash and cash equivalents of approximately \$1.7 million and marketable securities of approximately \$7.4 million invested in accordance with our investment policy, totaling approximately \$9.1 million, as compared to approximately \$3.1 million and approximately \$12.4 million as of December 31, 2016, totaling approximately \$15.5 million. The decrease is mainly attributable to our net loss of \$5.9 million during the six months ended June 30, 2017.

We had negative cash flow from operating activities of approximately \$6.7 million for the six months ended June 30, 2017, as compared to negative cash flow from operating activities of approximately \$6.1 million for the six months ended June 30, 2016. The negative cash flow from operating activities for the six months ended June 30, 2017 is mainly attributable to our net loss of approximately \$5.9 million, and as well, a decrease of approximately \$1.5 million of trade payables, other accounts payables and upfront fee from license agreement; partially offset by non-cash stock based compensation expenses of approximately \$709 thousand.

We had positive cash flow from investing activities of approximately \$5.1 million for the six months ended June 30, 2017, as compared to positive cash flow from investing activities of approximately \$5.0 million for the six months ended June 30, 2016. The positive cash flow from investing activities for both periods was primarily due to the consideration of marketable securities.

We had positive cash flow from financing activities of approximately \$247 thousand for the six months ended June 30, 2017, as compared to negative cash flow from financing activities of approximately \$132 thousand for the six months ended June 30, 2016. The positive cash flow from financing activities for the six months ended June 30, 2017 was due to proceeds from options exercise, while the negative cash flow from financing activities for the six months ended June 30, 2017 was due to issuance of ordinary shares net of issuance costs.

Although there can be no assurance, we believe that our existing cash resources will be sufficient to fund our projected cash requirements through the first half of 2018. Nevertheless, we will require significant additional financing in the future to fund our operations if and when we progress into Phase III trials of Aramchol and clinical trials for other indications, obtain regulatory approval of Aramchol and commercialize the drug. Our management may choose to raise such additional capital, which would be authorized by our board of directors, at their discretion.

## **Trend Information**

We are a development stage company, and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

## **Controls and Procedures**

As a “foreign private issuer”, we are only required to conduct the evaluations required by Rules 13a-15(b) and 13a-15(d) of the Exchange Act as of the end of each fiscal year and therefore have elected not to provide disclosure regarding such evaluations at this time.



**EXHIBIT INDEX**

**Exhibit No. Description**

99.1	Press Release, dated July 31, 2017
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Galmed Pharmaceuticals Ltd.**

Date: July 31, 2017 By: /s/ Allen Baharaff  
Allen Baharaff  
President and Chief Executive Officer